## CDK8-IN-1

Cat. No.: HY-103492 CAS No.: 1629633-48-2 Molecular Formula:  $C_{11}H_8F_3N_3O$ Molecular Weight: 255.2 Target: CDK

Pathway: Cell Cycle/DNA Damage

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (391.85 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
	1 mM	3.9185 mL	19.5925 mL	39.1850 mL	
	5 mM	0.7837 mL	3.9185 mL	7.8370 mL	
	10 mM	0.3918 mL	1.9592 mL	3.9185 mL	

Please refer to the solubility information to select the appropriate solvent.

# **BIOLOGICAL ACTIVITY**

Description	CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC <sub>50</sub> of 3 nM.				
IC <sub>50</sub> & Target	CDK8 3 nM (IC <sub>50</sub> )				
In Vivo	CDK8-IN-1 displays low systemic clearance, very good exposure and oral bioavailability. The $t_{max}$ is 0.25 h by PO. The mean values of $C_{max}$ are 9940 $\mu$ g/L, 12740 $\mu$ g/L by IV and PO respectively. The values of AUC are 9378, 25952 by IV and PO respectively <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

### **PROTOCOL**

 $\mathsf{Mice}^{[1]}$ Animal



CDK8-IN-1 is administrated to mice with 5 mg/kg, 25mg/mg by IV and PO respectively<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

	F				

[1]. Han X, et al. Discovery of potent and selective CDK8 inhibitors through FBDD approach. Bioorg Med Chem Lett. 2017 Sep 15;27(18):4488-4492.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA